Medical weight loss: what a good program includes

By the DieticiansWorldwide.com editorial team · 18 October 2026 · Weight management & GLP-1

What "medical weight loss" actually means

There is no legal definition of the phrase. Clinics use it for everything from a hospital obesity service with surgeons, physicians and psychologists, to a website that issues prescriptions after a short online form. What makes care genuinely medical is that a qualified clinician assesses your health, treats excess weight as a long-term condition rather than a willpower problem, and can use tools a commercial diet company cannot: prescription medicines, blood tests, management of related conditions and referral for surgery.

That framing reflects current guidance. Canada's adult obesity guideline says clinicians "can recognize and treat obesity as a chronic disease" and that "health professionals should not rely solely on BMI to predict an individual's health risk" (Obesity Canada). In practice, a good programme looks at your blood pressure, blood glucose, sleep, joints, mood, medicines and eating patterns before it talks about a target weight.

You will also see the terms "physician-supervised weight loss" and "GLP-1 weight loss clinic". The second usually means a service built around prescribing GLP-1 medicines such as semaglutide or tirzepatide. Those medicines can be very effective, but the label on the clinic tells you nothing about whether the rest of the care is there. Our weight management guide explains how medicines have reshaped the field and where nutrition care fits.

Who is it for?

Eligibility depends on the country, the treatment and your health, not on BMI alone. A few reference points:

• United States. The US Preventive Services Task Force (USPSTF) recommends that clinicians offer or refer adults with a BMI of 30 or more to intensive, multicomponent behavioural interventions, a grade B recommendation issued in September 2018 (USPSTF).
• England. NICE's guideline lists tirzepatide for adults with an initial BMI of at least 35 and at least one weight-related condition, and semaglutide within a specialist service for people with a BMI of 35 or more, or 30 to 34.9 if they meet the criteria for specialist referral. For both, thresholds are usually 2.5 points lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds (NICE NG246, medicines and surgery).
• Surgery. The same NICE section advises referral for a bariatric assessment for adults with a BMI of 40 or more, or 35 to 39.9 with a significant condition that weight loss could improve, provided they agree to long-term follow-up. The Canadian guideline uses similar BMI thresholds.

If you want a starting figure before an appointment, the BMI calculator gives the standard number and the waist-to-height ratio tool adds a measure of central fat. A clinician will interpret both alongside your medical history.

The seven parts of a complete programme

A useful way to judge any service is to check whether it covers each of the areas below. Missing one is not always a deal-breaker, but missing several usually is.

1. Assessment before treatment

Before anything is prescribed, expect a detailed history: how your weight has changed over time, what you have tried, your medical conditions and medicines, family history, pregnancy plans, alcohol, sleep, mood and eating behaviour, including any history of bingeing, restriction or purging. A nutrition and lifestyle advisory issued in 2025 by four US lifestyle, nutrition and obesity societies says that before GLP-1 treatment starts, "all individuals should undergo medical and nutritional assessment and screening" (American College of Lifestyle Medicine and partners, 2025). Baseline blood tests and measurements give a reference point for judging progress later.

2. Nutrition therapy from a qualified professional

This is the component most often thinned out or dropped. The Canadian guideline recommends that adults living with obesity "should receive individualized medical nutrition therapy provided by a registered dietitian (when available)", graded on the highest level of evidence. NICE's 2025 guideline asks that calorie-deficit eating plans come with help from a suitably trained professional, naming a Registered dietitian or registered nutritionist as examples, and with follow-up to sustain the loss (NICE NG246, physical activity and diet).

Good nutrition therapy is not a printed meal plan. It means a realistic energy target (the calorie calculator gives a rough estimate), enough protein to protect muscle, foods you actually like, and practical help with eating out, shift work, budgets and family meals. For some people with type 2 diabetes or a specific health goal, a specialist service may use a structured low-energy diet; NICE limits these to multicomponent programmes with long-term support. Whether shakes and bars have a place is covered in our meal replacement shakes guide. If you are unsure who is qualified, read how dietitians and nutritionists differ.

3. Physical activity, including strength work

Activity matters for health whether or not the scale moves, and strength training matters more when weight comes off quickly. For people on GLP-1 medicines, the 2025 advisory goes further, calling for a structured exercise plan with resistance work on three or more days each week alongside two and a half hours or more of moderate aerobic activity, adjusted to the person's fitness. A programme should help you start from where you are, which for many people means short walks and simple resistance exercises at home.

4. Behavioural support over months, not weeks

Behaviour change is where most of the long-term work happens: planning, self-monitoring, managing hunger and cravings, and getting back on track after a bad week. In the USPSTF evidence review, most effective intensive programmes lasted one to two years and had at least 12 sessions in the first year. People in those programmes were almost twice as likely as controls to lose 5% of their starting weight (risk ratio 1.94), and lost on average 2.39 kg more at 12 to 18 months. The Task Force adds that US regulators regard a 5% reduction as clinically meaningful.

5. Medication, when it fits

Prescribed medicines produce much larger average losses than behavioural support alone. STEP 1, which enrolled 1,961 adults without diabetes, found an average reduction of 14.9% with weekly semaglutide 2.4 mg over 68 weeks, compared with 2.4% for placebo; everyone also received lifestyle advice (Wilding and colleagues, NEJM 2021). Our article on GLP-1 weight loss covers the main trials, side effects and what happens when treatment stops.

A good programme also has clear rules for judging whether a medicine is working. NICE's technology appraisal for semaglutide recommends it for a maximum of 2 years within a specialist weight-management service, and says to consider stopping if less than 5% of starting weight has been lost after 6 months (NICE TA875). Medicines should be reviewed, not simply renewed.

6. Monitoring and a plan for stopping

NICE asks prescribers to monitor the effect of medicines, reinforce behavioural advice through regular review, and offer support to maintain weight loss to people who are stopping. Ask any clinic what happens at the end: how doses are reduced, how often you will be seen afterwards, and what the plan is if weight returns. Regain after stopping is common, so the eating and activity habits built during treatment are your insurance.

7. A route to surgery when appropriate

Some people gain most from bariatric surgery. A complete service either offers it or knows when to refer, and explains the lifelong commitments involved. NICE says people should be offered at least annual monitoring of nutritional status and supplementation after discharge from the surgical service. Our guide to bariatric multivitamins explains what that involves.

Medication-first or lifestyle-first?

This is the central debate in weight management now. One side argues that obesity is a chronic disease with powerful biology behind it, that medicines finally offer meaningful results, and that making people "fail" a diet before they qualify for treatment delays care. The other side points out that medicines work through reduced appetite, that diet quality and muscle preservation still depend on what people eat and do, and that habits matter if treatment stops.

The guidance sits between the two. NICE says weight-management medicines should be considered after dietary, exercise and behavioural approaches have been started and evaluated, and that all of them should be used alongside a reduced-calorie diet and more activity. In its semaglutide appraisal, the committee noted "there is no evidence of effectiveness if semaglutide is used as a single stand-alone treatment".

Trial evidence on adding intensive lifestyle support to medicine is mixed. The 2025 advisory notes that semaglutide combined with an intensive lifestyle programme in STEP 3 produced a 16% reduction in weight, against 14.9% with general advice in STEP 1, and that a 12-week intensive lifestyle phase followed by tirzepatide in SURMOUNT-3 produced a 25% reduction, the largest seen in GLP-1 trials so far. These were different trials with different participants, so the comparison is indirect. The practical conclusion is that the question is not which comes first, but whether both are present.

Weight-neutral care, stigma and outcome targets

A second debate is about what success means. Weight-neutral approaches focus on habits, fitness and health markers, and the Canadian guideline puts it bluntly: "Weight is not a behaviour and should not be a target for behaviour change." It also advises clinicians to ask permission before weighing someone. Others argue that weight loss of a defined size is what improves blood pressure, glucose, sleep apnoea and joint pain, and that clear targets help clinicians decide whether a treatment is worth continuing; the 5% review point used by NICE is an example.

These positions are less opposed than they sound. A respectful programme can set health goals you care about, track weight only with your consent, and still use outcome measures to decide whether a medicine is earning its place. What it should never do is shame you, blame you for slow progress, or treat every body the same.

Book a session with a dietitian

Safety: who needs extra care

• People taking insulin or a sulfonylurea. Eating less on any programme can push blood glucose too low. The US prescribing information for semaglutide 2.4 mg says this risk rises, sometimes severely, when it is used with insulin or medicines that stimulate insulin release, and that those doses may need lowering (FDA label via DailyMed). Never adjust any medicine yourself; changes must come from the prescriber.
• Pregnancy and planning a pregnancy. NICE's medicines table says not to use tirzepatide, semaglutide or liraglutide in pregnancy, and the US semaglutide label says to stop treatment two months or more before trying to conceive, because the drug stays in the body for a long time. Weight loss is not usually a goal during pregnancy.
• Eating disorders. Before a low-energy diet, NICE asks clinicians to offer assessment and counselling to anyone who may have an eating disorder. A sharp fall in appetite can hide restriction, so tell your team about any past or current difficulties.
• Pancreatitis and gallbladder problems. The semaglutide label describes possible signs of acute pancreatitis as persistent or severe abdominal pain, sometimes radiating to the back, with or without vomiting, and notes that rapid weight loss can raise the risk of gallstones. Severe or persistent abdominal pain needs urgent medical review.
• Older adults. Rapid loss on a low-protein, inactive routine tends to take muscle with it. Our guide to weight loss in older adults explains how to protect strength and function.

Costs, insurance and NHS access

Prices for private programmes vary too widely by country, clinic and medicine to quote reliably. Ask for a written breakdown covering consultations, the medicine itself, blood tests, dietitian sessions and how long follow-up lasts, because a low monthly fee can exclude most of the care.

• US Medicare. Part B covers obesity screening and behavioural counselling for people with a BMI of 30 or more, delivered by a primary care provider in a primary care setting, at no cost if the provider accepts assignment. The same Medicare page describes the Medicare GLP-1 Bridge, which gives eligible Part D enrollees certain GLP-1 drugs for a $50 copayment for a one-month supply (Medicare.gov). Private plans set their own rules; our guide on whether insurance covers a dietitian lists the questions to ask.
• England. NHS access to tirzepatide is being phased in. NICE's summary of NHS England's interim commissioning guidance says people with four or more listed conditions and a BMI of 40 or more were eligible first, with access widening from around June 2026 to people with a BMI of 35 to 39.9, and from around March 2027 to people with three conditions and a BMI of 40 or more (NICE TA1026). More detail on UK care routes is in the United Kingdom country guide.

Red flags in marketing and prescribing

Compounded copies of GLP-1 medicines are a particular concern. The US Food and Drug Administration points out that they do not go through its approval process, and tells consumers to be suspicious of sellers who say a compounded product is identical to a licensed one, charge unusually low prices, or supply medicine without a licensed doctor screening and prescribing for them. As of 31 May 2026, it had received 990 adverse event reports linked to compounded semaglutide and more than 730 for compounded tirzepatide, and it notes that some reported events, including hospitalisations, may be related to dosing errors (FDA).

Advertising claims deserve the same scepticism. The Federal Trade Commission's reference guide for media lists claims that are almost always false, including that a product "causes permanent weight loss even after the consumer stops using product" or "causes substantial weight loss for all users" (FTC Gut Check). A legitimate medical service will talk about ranges, side effects and uncertainty, not guarantees.

Questions to ask before you sign up

1. Who will assess me, and what are their qualifications and registration?
2. Will I see a registered dietitian, and how often?
3. What blood tests and measurements do you take at the start and during treatment?
4. How do you decide whether a medicine is working, and when would you stop it?
5. What happens if I have side effects, and who do I contact out of hours?
6. What is the plan for maintenance, and what does follow-up cost after the first months?
7. Do you screen for eating disorders and ask about pregnancy plans?

If you are still deciding between a medical service and other options, our guide to choosing a weight management programme compares the main types, and our comparison of online weight loss programmes covers remote and telehealth services in detail.